Biotech Support Group Introduces HemoVoid™ Blood Card for Hemoglobin Removal/Depletion for Biomarker Studies.

Biotech Support Group Introduces HemoVoid™ Blood Card For Hemoglobin Removal/Depletion For Biomarker Studies.

Biotech Support Group has developed a unique product for depletion of hemoglobin and enrichment of other blood proteins from dried blood spots (DBS). The DBS technique has several advantages of being minimally invasive(finger prick instead of venous blood collection) with numerous applications in drug metabolism (DM), pharmacokinetic (PK) and toxicokinetic (TK) studies. A major advantage of DBS is ease of transporting blood samples, simple storage/ shipping amenable to non-clinical settings and allowing ease of transfer of samples thereby reducing the infection risk of various blood pathogens. The DBS require blood volumes of 10ul to 50ul per sample thus reducing costs of research studies. Recently published articles from Li et al has suggested scientists are implementing DBS in combination with LC-MS/MS for quantitative analysis of small molecules.

Although DBS has advantages, removing hemoglobin from samples of DBS has been difficult until now because Hemovoid™ Blood Card is technologically sophisticated for separating/depleting hemoglobin from other blood proteins. The HemoVoid™ Blood Card produces enriched proteins free of hemoglobin which are used for biomarkers and protein analysis(B). The hemoglobin enriched filtrate could have hemoglobin variants, hemoglobin binding proteins or other analytes optimal for biomarker studies(A).

The HemoVoid™ protocol uses mild buffers; the protocol conditions are so gentle that native enzyme activity is retained in elution fractions. Thus the enzyme activity is retained and functions of protein are preserved. HemoVoid™ Blood Card allows scientists to study sources of blood biomarkers because the hemoglobin is removed from whole blood lysates that are extracted from dried blood cards. This technique works for samples of both frozen and fresh whole blood and proteins in the blood are enriched for potential biomarker and proteomic studies. Based on the HemoVoid™ Blood Card protocol, a starting sample of 10ul-50ul, the average hemoglobin removal is >98%.

Biotech Support Group has other hemoglobin removal products such as:
HemogloBind™ Hemoglobin Depletion From Hemolyzed Serum/Plasma
HemoVoid™ - Hemoglobin Depletion From Erythrocytes

Published Hemovoid™ References

• Mizukawa, B., George, A., Pushkaran, S., Weckbach, L., Kalinyak, K., Heubi, J. E. and Kalfa, T. A. ,Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis.Pediatric Blood & Cancer.
• Functional 20S proteasomes in mature human red blood cells Sudha Neelam¹, David G Kakhniashvili¹, Stephan Wilkens¹,Stephen D Levene² and Steven R Goodman1 Exp. Biol. Med. 2011;236:580-591 doi:10.1258/ebm.2011.010394

Suggested References:

• M Barfield and R Wheller (2011) Use of Dried Plasma Spots in the Determination of Pharmacokinetics in Clinical Studies: Validation of a Quantitative Bioanalytical Method. Analytical Chemistry 83 (1), 118-124.
• Li, W. and Tse, F. L. S. (2010), Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomedical Chromatography, 24: 49–65
• Liang X, et al. Study of Dried Blood Spots Techniques for the Determination of Dextromethorphan and Its Metabolite Dextrorphan in Human Whole Blood by LC-MS/MS, J Chromatograph B. 2009; 877: 799-806.
• Spooner N. et al. Dried Blood Spots as a Sample Collection Technique for the Determination of Pharmacokinetics in Clinical Studies: Considerations for the Validation of a Quantitative Bioanalytical Method, Anal Chem. 2009;81:1557- 1563.
• Barfield M, et al. Application of Dried Blood Spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies, J Chromatograph B. 2008;870:32-37.
• Lin YS, McKelvey W, Waidyanatha S, Rappaport SM. Variability of albumin adducts of 1,4-benzoquinone, a toxic metabolite of benzene, in human volunteers.Biomarkers 2006;11:14–27
• Beaudette P, et al. Discovery Stage Pharmacokinetics Using Dried Blood Spots, J Chromatograph B. 2004;809:153-158. Rappaport SM, Waidyanatha S, Qu Q, et al. Albumin adducts of benzene oxide and 1,4-benzoquinone as measures of human benzene metabolism. Cancer Res2002;62:1330–7.
• Tornqvist M, Fred C, Haglund J, Helleberg H, Paulsson B, Rydberg P. Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. J Chromatogr B Analyt Technol Biomed Life Sci 2002;778:279–308.
• Yeowell-O'Connell K, McDonald TA, Rappaport SM. Analysis of hemoglobin adducts of benzene oxide by gas chromatography-mass spectrometry. Anal Biochem 1996;237:49–55.
• Yeowell-O'Connell K, Rothman N, Smith MT, et al. Hemoglobin and albumin adducts of benzene oxide among workers exposed to high levels of benzene.Carcinogenesis 1998;19:1565–71